EE04439B1 - 5HT1 antagonistid antidepressantraviks - Google Patents

5HT1 antagonistid antidepressantraviks

Info

Publication number
EE04439B1
EE04439B1 EEP200100346A EEP200100346A EE04439B1 EE 04439 B1 EE04439 B1 EE 04439B1 EE P200100346 A EEP200100346 A EE P200100346A EE P200100346 A EEP200100346 A EE P200100346A EE 04439 B1 EE04439 B1 EE 04439B1
Authority
EE
Estonia
Prior art keywords
antagonists
antidepressant therapy
antidepressant
therapy
Prior art date
Application number
EEP200100346A
Other languages
English (en)
Estonian (et)
Inventor
Michael Bright Gene
Amratlal Desai Kishor
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of EE200100346A publication Critical patent/EE200100346A/xx
Publication of EE04439B1 publication Critical patent/EE04439B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EEP200100346A 1998-12-28 1999-11-03 5HT1 antagonistid antidepressantraviks EE04439B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11395798P 1998-12-28 1998-12-28
PCT/IB1999/001772 WO2000039128A1 (en) 1998-12-28 1999-11-03 5ht1 antagonists for antidepressant therapy

Publications (2)

Publication Number Publication Date
EE200100346A EE200100346A (et) 2002-12-16
EE04439B1 true EE04439B1 (et) 2005-02-15

Family

ID=22352526

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100346A EE04439B1 (et) 1998-12-28 1999-11-03 5HT1 antagonistid antidepressantraviks

Country Status (43)

Country Link
US (1) US6525196B1 (uk)
EP (1) EP1140931B1 (uk)
JP (1) JP2002533463A (uk)
KR (1) KR100417506B1 (uk)
CN (1) CN1332740A (uk)
AP (1) AP2001002188A0 (uk)
AR (1) AR024840A1 (uk)
AT (1) ATE260278T1 (uk)
AU (1) AU761711B2 (uk)
BG (1) BG105710A (uk)
BR (1) BR9916807A (uk)
CA (1) CA2356985C (uk)
CO (1) CO5150179A1 (uk)
CR (1) CR6398A (uk)
CZ (1) CZ291163B6 (uk)
DE (1) DE69915113T2 (uk)
DK (1) DK1140931T3 (uk)
DZ (1) DZ2933A1 (uk)
EA (1) EA003099B1 (uk)
EE (1) EE04439B1 (uk)
ES (1) ES2214892T3 (uk)
GE (1) GEP20043227B (uk)
GT (1) GT199900224A (uk)
HR (1) HRP20010488A2 (uk)
HU (1) HUP0104852A3 (uk)
ID (1) ID30117A (uk)
IL (1) IL143385A0 (uk)
IS (1) IS5951A (uk)
MA (1) MA26706A1 (uk)
NO (1) NO20013215L (uk)
NZ (1) NZ511964A (uk)
OA (1) OA11742A (uk)
PA (1) PA8486701A1 (uk)
PE (1) PE20001234A1 (uk)
PT (1) PT1140931E (uk)
SK (1) SK9002001A3 (uk)
TN (1) TNSN99218A1 (uk)
TR (1) TR200101979T2 (uk)
TW (1) TW523514B (uk)
UA (1) UA62015C2 (uk)
WO (1) WO2000039128A1 (uk)
YU (1) YU44301A (uk)
ZA (1) ZA200105041B (uk)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003065970A2 (en) * 2001-02-20 2003-08-14 Royal College Of Surgeons Ie Treatment of fibromyalgia and related fatigue syndromes using pindolol
GB0203778D0 (en) * 2002-02-18 2002-04-03 Glaxo Group Ltd Compounds
AP2005003390A0 (en) * 2003-03-12 2005-09-30 Pfizer Prod Inc Pyridyloxymethyl and benzisoxazole azabicyclic derivatives.
GB0316915D0 (en) * 2003-07-18 2003-08-20 Glaxo Group Ltd Compounds
WO2005082370A1 (en) * 2004-01-29 2005-09-09 Pfizer Products Inc. Combinations of an atypical antipsychotic and an aminomethylpyridyloxymethyl/benzisoxazole azabicyclic derivatives for treating cns disorders
AR048112A1 (es) * 2004-03-25 2006-03-29 Solvay Pharm Bv Derivados de 1-(2h-1-benzopiran-2-on-8-il)-piperazina para el tratamiento de dolor
AR049478A1 (es) 2004-03-25 2006-08-09 Solvay Pharm Bv Un procedimiento para la preparacion de 3-amino-8-(1-piperazinil)-2h-1-benzopiran-2-ona. sales e hidratos y composiciones farmaceuticas.
BRPI0515143A (pt) * 2004-09-10 2008-07-08 Pfizer Prod Inc usos de derivados azabicìclicos de piridiloximetila e benzisoxazol para a preparação de uma composição farmacêutica para o tratamento dos distúrbios de humor
JP2008512441A (ja) * 2004-09-10 2008-04-24 ファイザー・プロダクツ・インク ピリジルオキシメチル、及びベンズイソオキサゾール・アザビシクロ誘導体を使用する、認知障害の治療方法
DE102005026194A1 (de) * 2005-06-06 2006-12-07 Grünenthal GmbH Substituierte N-Benzo[d]isoxazol-3-yl-amin-Derivate und deren Verwendung zur Herstellung von Arzneimitteln
WO2008019431A1 (en) * 2006-08-14 2008-02-21 Brc Operations Pty Limited Method and compositions for simultaneously regulating memory and mood
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2020183011A1 (en) 2019-03-14 2020-09-17 Institut Curie Htr1d inhibitors and uses thereof in the treatment of cancer
WO2021127391A1 (en) * 2019-12-20 2021-06-24 The Jackson Laboratory Molecular targets for addiction

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5157034A (en) * 1991-02-27 1992-10-20 Pfizer Inc. Neuroleptic perhydro-1H-pyrido[1,2-a]pyrazines
GB9410512D0 (en) * 1994-05-25 1994-07-13 Smithkline Beecham Plc Novel treatment
US5756496A (en) * 1994-05-28 1998-05-26 Smithkline Beecham P.L.C. Amide derivatives having 5HT1D-antagonist activity
IL132409A0 (en) * 1997-04-18 2001-03-19 Smithkline Beecham Plc Indole derivatives having combined 5ht1a 5ht1b and 5ht1d receptor antagonist activity
IT1293807B1 (it) * 1997-08-01 1999-03-10 Recordati Chem Pharm Derivati 1- (n-fenilaminoalchil) piperazinici sostituiti alla posizione 2 dell'anello fenilico
PA8469101A1 (es) * 1998-04-09 2000-09-29 Pfizer Prod Inc Ligandos azabiciclicos de receptores 5ht1

Also Published As

Publication number Publication date
ATE260278T1 (de) 2004-03-15
GT199900224A (es) 2001-06-15
HRP20010488A2 (en) 2002-08-31
YU44301A (sh) 2004-07-15
DE69915113T2 (de) 2004-08-26
OA11742A (en) 2005-05-13
PT1140931E (pt) 2004-05-31
DE69915113D1 (de) 2004-04-01
IL143385A0 (en) 2002-04-21
BG105710A (en) 2002-02-28
TNSN99218A1 (fr) 2005-11-10
GEP20043227B (en) 2004-04-26
BR9916807A (pt) 2001-10-23
HUP0104852A3 (en) 2002-12-28
NO20013215L (no) 2001-08-27
CR6398A (es) 2004-03-24
PE20001234A1 (es) 2000-11-07
CZ20012386A3 (cs) 2002-02-13
HUP0104852A2 (hu) 2002-05-29
CZ291163B6 (cs) 2003-01-15
AU6361499A (en) 2000-07-31
US6525196B1 (en) 2003-02-25
PA8486701A1 (es) 2000-09-29
EA200100517A1 (ru) 2001-12-24
WO2000039128A1 (en) 2000-07-06
KR100417506B1 (ko) 2004-02-05
SK9002001A3 (en) 2002-04-04
CO5150179A1 (es) 2002-04-29
AP2001002188A0 (en) 2001-06-30
CA2356985C (en) 2006-08-08
EP1140931A1 (en) 2001-10-10
NZ511964A (en) 2003-08-29
AU761711B2 (en) 2003-06-05
EA003099B1 (ru) 2002-12-26
DK1140931T3 (da) 2004-04-19
CN1332740A (zh) 2002-01-23
TR200101979T2 (tr) 2001-12-21
NO20013215D0 (no) 2001-06-27
EP1140931B1 (en) 2004-02-25
UA62015C2 (en) 2003-12-15
ES2214892T3 (es) 2004-09-16
IS5951A (is) 2001-05-22
KR20010092455A (ko) 2001-10-25
CA2356985A1 (en) 2000-07-06
ZA200105041B (en) 2002-06-20
DZ2933A1 (fr) 2004-03-15
TW523514B (en) 2003-03-11
AR024840A1 (es) 2002-10-30
ID30117A (id) 2001-11-08
MA26706A1 (fr) 2004-12-20
JP2002533463A (ja) 2002-10-08
EE200100346A (et) 2002-12-16

Similar Documents

Publication Publication Date Title
NO20003640D0 (no) Ny doseringsform
ID27841A (id) Turunan-turunan biaril terapeutik
IS6024A (is) Ný efnasambönd
PT1202994E (pt) Novos compostos
DE69834019D1 (de) Dose
IS5699A (is) Ný notkun
FI4209U1 (fi) Uusia yhdisteitä
NO994626D0 (no) Substituerte benzamider
IS6139A (is) Ný efnasambönd
NO20013215D0 (no) 5HT1 antagonister for antidepressiv terapi
ID26086A (id) Ligan-ligan reseptor 5ht1 azabisiklik
NO20003694D0 (no) VLA-4 antagonister
ID27845A (id) Turunan tetrahidrokuilina sebagai antagonis glisilina
SI1140931T1 (en) 5ht1 antagonists for antidepressant therapy
SE9802023D0 (sv) New therapeutic use
SE9902762D0 (sv) New compounds
SE9904418D0 (sv) New compounds
SE9900071D0 (sv) New compounds
SE9900086D0 (sv) New compounds
SE9801099D0 (sv) New compounds
SE9803746D0 (sv) New compounds
SE9800512D0 (sv) New compounds
SE9800511D0 (sv) New compounds
SE9800510D0 (sv) New Compounds
SE9803747D0 (sv) New compounds

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20051231

MM4A Lapsed by not paying the annual fees

Effective date: 20051103